iTeos TherapeuticsITOS
ITOS
About: ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
Employees: 157
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
585% more call options, than puts
Call options by funds: $27M | Put options by funds: $3.94M
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
30% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 43
10% more funds holding
Funds holding: 136 [Q2] → 149 (+13) [Q3]
2.98% less ownership
Funds ownership: 104.43% [Q2] → 101.44% (-2.98%) [Q3]
32% less capital invested
Capital invested by funds: $560M [Q2] → $378M (-$182M) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
138%
upside
Avg. target
$20
150%
upside
High target
$21
163%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 34% 1-year accuracy 63 / 188 met price target | 163%upside $21 | Buy Reiterated | 16 Jan 2025 |
Wells Fargo Eva Fortea Verdejo 20% 1-year accuracy 1 / 5 met price target | 138%upside $19 | Overweight Maintained | 19 Dec 2024 |
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Negative
Seeking Alpha
1 month ago
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
iTeos Therapeutics, Inc.'s lead candidate, belrestotug, shows promising response rates in lung cancer but faces challenges with increased toxicity and skepticism due to past failures in similar approaches. The company's financial health is strong, with over half a billion dollars in liquid assets and long-term investments, providing a substantial cushion for ongoing projects. Despite shelving inupadenant, the focus remains on belrestotug, with ongoing trials exploring its potential in various cancer indications.
Neutral
GlobeNewsWire
1 month ago
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS - Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed - Inupadenant deprioritized to focus resources on other programs
Neutral
GlobeNewsWire
1 month ago
iTeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December:
Neutral
GlobeNewsWire
2 months ago
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU - Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO - Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination - Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones
Negative
Investors Business Daily
4 months ago
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
Negative
Benzinga
4 months ago
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday.
Positive
Seeking Alpha
4 months ago
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT
iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 years of cash runway, bolstered by collaboration revenue, supporting its potential to reach critical milestones. The risks include small trial size, potential non-translation of response rates to survival benefits, and high-grade toxicities that could hinder approval.
Neutral
GlobeNewsWire
4 months ago
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy - Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations - GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting - iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET
Neutral
GlobeNewsWire
4 months ago
iTeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in September:
Charts implemented using Lightweight Charts™